- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01787084
Alternative Access Approaches for Transcatheter Aortic Valve Replace (TAVR) in Inoperable Patients With Aortic Stenosis (Inop AA)
Transcatheter Valve Therapy (TVT) Registry Assessment of Alternative Access Approaches for Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Transcatheter aortic valve replacement (TAVR) using the Edwards SAPIEN valve and Retroflex 3 delivery system provides both a mortality and quality of life benefit for inoperable patients. Only the transfemoral (TF) access has been approved in the US. A substantial number of patients cannot have a TF approach due to inadequate vessel size, vessel disease, or other anatomical considerations. The pivotal study did not include an assessment of safety and effectiveness of alternative access approaches in this inoperable patient group.
Early approaches to TAVR included a femoral transvenous approach with transseptal access to the left side for delivery of the valve. This approach avoided large bore arterial catheterization, but it had unacceptable rates of complications and lacked reproducibility. Alternative access approaches have been developed because of the risks associated with inserting large caliber catheters into small, diseased femoral arteries often associated with diffuse vasculopathy. To avoid the vascular complications from femoral access, other transcatheter approaches have been developed to include open surgical access to the left ventricular apex (TA), ascending aorta, (TAO), subclavian and axillary arteries (TS), and retroperitoneal access to the iliac artery (TI) as well as distal aorta. In addition to providing TAVR to patients who cannot have TF access, additional advantages include better catheter control and safer closure of the access site. Commonly cited disadvantages include the need for surgical expertise and additional equipment, along with the potential for longer recovery, more incisional pain, greater radiation exposure for operators, unsuitable delivery catheters for alternative access sites, and a host of unique alternative access site complications.
We propose to collectively analyze 30-day safety endpoints as a lumped data group for these alternative access approaches. These data are gathered from clinical practice in real-world settings and submitted to the TVT Registry. It is expected that centers will choose among the various choices for alternative access based the causative factors underlying the need for alternative access, as well as local skill sets and experience. For this lumped data group of alternative access approaches we will compare 30-day safety results to the TA outcomes reported from Cohort A of the PARTNERS 1 trial. We recognize that these TA patients were high risk operable patients rather than inoperable patients, but no other direct comparator group is available. We reason that the TA data from this published clinical trial are high quality, represent an alternative access approach rather than TF, and will provide a frequency of safety endpoints that have been found to be acceptable both clinically and from a regulatory perspective.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 18 years or older
- Primary indication is symptomatic primary severe aortic stenosis predicted to benefit from relief of valvular stenosis
- Aortic valve area less than 0.8 centimeters squared
- Mean aortic valve gradient greater than or equal to 40 mmHG
- Peak aortic jet velocity greater than or equal to 4.0 m per second
- Valve sheath access site is femoral, axillary, transapical, transaortic, subclavian or subaxillary
- Patient is judged by the local heart team to be inoperable for Aortic Valve Replacement due to severe chest wall deformities or radiation effects, severe peripheral or aortic vascular disease, or severe systemic disease prohibiting the safe conduct of Cardiopulmonary Bypass (CPB)
Exclusion Criteria:
- Aortic valve annulus size is less than 18 mm or greater than 25 mm
- Active infectious endocarditis
- Valve in prosthetic valve procedure
- Patients considered by the heart team to be unlikely to receive meaningful or durable clinical benefit from the procedure
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Inoperable Patients Alternative Access
Non-femoral delivery (or alternative access) in patients iwht severe symptomatic native aortic valve stenosis who have been determined by a cardiac surgeon to be inoperable for open aortic valve replacement and in whom existing co-morbidities would not preclude the expected benefit from correction of the aortic stenosis
|
Non-femoral transcatheter delivery of heart valve
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major adverse cardiac and cerebrovascular events
Time Frame: 30 day
|
Increase in the 30-day risk of adverse events among patients receiving TAVR; Modified 30 day Valve Academic Research Consortium (VARC) Composite Early Safety Endpoint
|
30 day
|
Mortality
Time Frame: 1 year
|
Proportion of patients who are alive with at least moderate functional improvement (defined as at least 10 point improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline) at 1 year after TAVR
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
30-day endpoints for major morbidity
Time Frame: 30 day
|
Endpoints include: mortality, stroke, stroke or transient ischemic attack (TIA), major vascular complications, valve-related dysfunction requiring re-intervention, incident renal replacement therapy, life-threatening bleeding, and high-degree aortic valve (AV) block requiring permanent pacemaker implantation
|
30 day
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TVTR-2012-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Symptomatic Aortic Stenosis
-
University Hospital, RouenCompleted
-
Edwards LifesciencesActive, not recruitingSymptomatic Severe Aortic StenosisUnited States
-
Edwards LifesciencesCompletedSymptomatic Severe Aortic StenosisUnited States, Canada
-
University of MichiganWithdrawnSevere Symptomatic Aortic StenosisUnited States
-
Abbott Medical DevicesRecruitingSymptomatic Severe Aortic StenosisSpain, Denmark, United Kingdom, France, Italy, Australia, Germany, Netherlands, Switzerland, Austria
-
Edwards LifesciencesCompletedSymptomatic Severe Aortic StenosisUnited States, Canada
-
Medtronic CardiovascularActive, not recruiting
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
University Hospital, MontpellierCompletedSevere and Symptomatic Aortic StenosisFrance
-
Edwards LifesciencesAmerican College of CardiologyCompletedCalcific Aortic Stenosis | Severe | SymptomaticUnited States
Clinical Trials on Edwards SAPIEN Transcatheter Heart Valve
-
Edwards LifesciencesCompletedAortic Valve DiseaseUnited Kingdom, France, Germany, Italy, Canada
-
National Heart, Lung, and Blood Institute (NHLBI)Completed
-
Edwards LifesciencesCompletedCritical Aortic StenosisUnited States, Canada, Germany
-
University of California, Los AngelesCompletedEisenmenger SyndromeUnited States
-
Edwards LifesciencesActive, not recruitingHeart Failure | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve DiseaseUnited States, Australia, Brazil
-
Edwards LifesciencesCompletedAortic Stenosis | Cardiomyopathy, HypertrophicUnited States, Canada
-
Edwards LifesciencesRecruiting
-
Edwards LifesciencesCompletedPulmonary Regurgitation | Pulmonary Insufficiency | Pulmonary StenosisGermany, Ireland, Belgium, Israel, United Kingdom, Italy, Poland, Saudi Arabia, Turkey
-
UMC UtrechtTerminatedPeriprosthetic Aortic Valve Regurgitation After TAVINetherlands
-
University Hospital Inselspital, BerneCompletedAortic Valve StenosisNetherlands, Germany, Switzerland, United Kingdom